Effects of a proteasome inhibitor on the riboflavin production in Ashbya gossypii

J Appl Microbiol. 2022 Feb;132(2):1176-1184. doi: 10.1111/jam.15296. Epub 2021 Sep 17.

Abstract

Aims: Effects of a proteasome inhibitor, MG-132, on the riboflavin production in Ashbya gossypii were investigated to elucidate the relationship of the riboflavin production with flavoprotein homeostasis.

Methods and results: The addition of MG-132 to the liquid medium reduced the specific riboflavin production by 79% in A. gossypii at 25 μM after 24 h. The addition of the inhibitor also caused the accumulation of reactive oxygen species and ubiquitinated proteins. These results indicated that MG-132 works in A. gossypii without any genetic engineering and reduces riboflavin production. In the presence of 25 μM MG-132, specific NADH dehydrogenase activity was increased by 1.4-fold compared to DMSO, but specific succinate dehydrogenase (SDH) activity was decreased to 52% compared to DMSO. Additionally, the amount of AgSdh1p (ACR052Wp) was also reduced. Specific riboflavin production was reduced to 22% when 20 mM malonate, a SDH inhibitor, was added to the culture medium. The riboflavin production in heterozygous AgSDH1 gene-disrupted mutant (AgSDH1-/+ ) was reduced to 63% compared to that in wild type.

Conclusions: MG-132 suppresses the riboflavin production and SDH activity in A. gossypii. SDH is one of the flavoproteins involved in the riboflavin production in A. gossypii.

Significance and impact of the study: This study shows that MG-132 has a negative influence on the riboflavin production and SDH activity in A. gossypii and leads to the elucidation of the connection of the riboflavin production with flavoproteins.

Keywords: Ashbya gossypii; MG-132; riboflavin; succinate dehydrogenase.

MeSH terms

  • Genetic Engineering
  • Leupeptins / pharmacology
  • Proteasome Inhibitors* / pharmacology
  • Riboflavin* / biosynthesis
  • Saccharomycetales / drug effects
  • Saccharomycetales / metabolism*

Substances

  • Leupeptins
  • Proteasome Inhibitors
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  • Riboflavin

Grants and funding